canakinumab
novartis
['lcsm,(-blcsm)', 'nsclc', 'canakinumab', 'canopy-a', 'sclc']
#esmo22 #lcsm
canakinumab in adjuvant setting for nsclc (canopy-a trial) for cana, again, another failure! that s it! the end of the potential story 
Thoracic oncologist & researcher @IEOufficiale; @myESMO Press & Media Chair; #LungCancer Molecular target-believer #LCSM